A novel resveratrol derivative induces mitotic arrest, centrosome fragmentation and cancer cell death by inhibiting γ-tubulin.

Cancer cell proliferation Centrosome fragmentation Resveratrol analogues Tubulin polymerization γ-tubulin

Journal

Cell division
ISSN: 1747-1028
Titre abrégé: Cell Div
Pays: England
ID NLM: 101251560

Informations de publication

Date de publication:
2019
Historique:
received: 14 12 2018
accepted: 23 03 2019
entrez: 23 4 2019
pubmed: 23 4 2019
medline: 23 4 2019
Statut: epublish

Résumé

Resveratrol and its natural stilbene-containing derivatives have been extensively investigated as potential chemotherapeutic agents. The synthetic manipulation of the stilbene scaffold has led to the generation of new analogues with improved anticancer activity and better bioavailability. In the present study we investigated the anticancer activity of a novel trimethoxystilbene derivative (3,4,4'-trimethoxylstilbene), where two methoxyl groups are adjacent on the benzene ring (ortho configuration), and compared its activity to 3,5,4'-trimethoxylstilbene, whose methoxyl groups are in meta configuration. We provide evidence that the presence of the two methoxyl groups in ortho configuration renders 3,4,4'-trimethoxystilbene more efficient than the meta isomer in inhibiting cell proliferation and producing apoptotic death in colorectal cancer cells. Confocal microscopy of α- and γ-tubulin staining shows that the novel compound strongly depolymerizes the mitotic spindle and produces fragmentation of the pericentrosomal material. Computer assisted docking studies indicate that both molecules potentially interact with γ-tubulin, and that 3,4,4'-trimethoxystilbene is likely to establish stronger interactions with the protein. These findings demonstrate the ortho configuration confers higher specificity for γ-tubulin with respect to α-tubulin on 3,4,4' trimethoxystilbene, allowing it to be defined as a new γ-tubulin inhibitor. A strong interaction with γ-tubulin might be a defining feature of molecules with high anticancer activity, as shown for the 3,4,4' isomer.

Sections du résumé

BACKGROUND BACKGROUND
Resveratrol and its natural stilbene-containing derivatives have been extensively investigated as potential chemotherapeutic agents. The synthetic manipulation of the stilbene scaffold has led to the generation of new analogues with improved anticancer activity and better bioavailability. In the present study we investigated the anticancer activity of a novel trimethoxystilbene derivative (3,4,4'-trimethoxylstilbene), where two methoxyl groups are adjacent on the benzene ring (ortho configuration), and compared its activity to 3,5,4'-trimethoxylstilbene, whose methoxyl groups are in meta configuration.
RESULTS RESULTS
We provide evidence that the presence of the two methoxyl groups in ortho configuration renders 3,4,4'-trimethoxystilbene more efficient than the meta isomer in inhibiting cell proliferation and producing apoptotic death in colorectal cancer cells. Confocal microscopy of α- and γ-tubulin staining shows that the novel compound strongly depolymerizes the mitotic spindle and produces fragmentation of the pericentrosomal material. Computer assisted docking studies indicate that both molecules potentially interact with γ-tubulin, and that 3,4,4'-trimethoxystilbene is likely to establish stronger interactions with the protein.
CONCLUSIONS CONCLUSIONS
These findings demonstrate the ortho configuration confers higher specificity for γ-tubulin with respect to α-tubulin on 3,4,4' trimethoxystilbene, allowing it to be defined as a new γ-tubulin inhibitor. A strong interaction with γ-tubulin might be a defining feature of molecules with high anticancer activity, as shown for the 3,4,4' isomer.

Identifiants

pubmed: 31007707
doi: 10.1186/s13008-019-0046-8
pii: 46
pmc: PMC6457039
doi:

Types de publication

Journal Article

Langues

eng

Pagination

3

Déclaration de conflit d'intérêts

The authors declare that they have no competing interests.

Références

J Cell Biol. 2000 Sep 4;150(5):975-88
pubmed: 10973989
J Med Chem. 2003 Jul 31;46(16):3546-54
pubmed: 12877593
Int J Cancer. 2003 Nov 1;107(2):189-96
pubmed: 12949793
Nature. 2004 Mar 11;428(6979):198-202
pubmed: 15014504
J Nutr Biochem. 2005 Aug;16(8):449-66
pubmed: 16043028
Bioorg Chem. 2006 Jun;34(3):142-57
pubmed: 16712899
Neurochem Res. 2007 Aug;32(8):1387-98
pubmed: 17406983
Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5378-83
pubmed: 18388201
Cell. 1991 May 31;65(5):825-36
pubmed: 1840506
J Comput Chem. 2009 Dec;30(16):2785-91
pubmed: 19399780
Nature. 2009 Jul 9;460(7252):278-82
pubmed: 19506557
J Cell Physiol. 2009 Dec;221(3):514-20
pubmed: 19650077
PLoS One. 2009 Aug 10;4(8):e6564
pubmed: 19668340
Curr Biol. 2009 Dec 1;19(22):1937-42
pubmed: 19879145
J Cell Physiol. 2010 May;223(2):519-29
pubmed: 20162618
Eur J Med Chem. 2010 Jul;45(7):2972-80
pubmed: 20395019
Drug Discov Today. 2010 Sep;15(17-18):757-65
pubmed: 20692359
Bioorg Med Chem Lett. 2010 Dec 1;20(23):6938-41
pubmed: 20970329
Eur J Med Chem. 2011 Jun;46(6):2586-95
pubmed: 21497957
Nat Rev Mol Cell Biol. 2011 Jun;12(6):385-92
pubmed: 21527953
Nat Rev Mol Cell Biol. 2011 Oct 12;12(11):709-21
pubmed: 21993292
Chem Biol Drug Des. 2012 May;79(5):639-52
pubmed: 22268380
Ann N Y Acad Sci. 2013 Jul;1290:12-20
pubmed: 23855461
Chem Biol Interact. 2013 Nov 25;206(2):175-85
pubmed: 24075811
Nature. 2014 Jun 5;510(7503):167-71
pubmed: 24739973
Nat Cell Biol. 2014 May;16(5):386-94
pubmed: 24914434
Philos Trans R Soc Lond B Biol Sci. 2014 Sep 5;369(1650):null
pubmed: 25047621
Biochim Biophys Acta. 2015 Jun;1852(6):1178-85
pubmed: 25446990
Oncotarget. 2015 Apr 30;6(12):10487-97
pubmed: 25868856
Toxicol Appl Pharmacol. 2015 Aug 15;287(1):67-76
pubmed: 26044878
Nat Commun. 2015 Oct 27;6:8722
pubmed: 26503935
Nat Rev Mol Cell Biol. 2015 Dec;16(12):711-26
pubmed: 26562752
Sci Rep. 2016 Jul 06;6:28922
pubmed: 27380724
Br J Clin Pharmacol. 2017 Feb;83(2):255-268
pubmed: 27620987
Mol Carcinog. 2017 Mar;56(3):1117-1126
pubmed: 27739192
Adv Exp Med Biol. 2017;1002:93-124
pubmed: 28600784
Int J Mol Sci. 2017 Jul 04;18(7):null
pubmed: 28677634
Ann N Y Acad Sci. 2017 Sep;1403(1):59-69
pubmed: 28945938
Histol Histopathol. 2019 Jan;34(1):81-90
pubmed: 30010174

Auteurs

Gianandrea Traversi (G)

1Department of Science, University of "Roma Tre", Rome, Italy.

David Sasah Staid (DS)

2Department of Biochemical Sciences 'A. Rossi Fanelli', Sapienza University of Rome, Rome, Italy.

Mario Fiore (M)

3Institute of Molecular Biology and Pathology, National Research Council of Italy (CNR), c/o Sapienza University of Rome, Rome, Italy.

Zulema Percario (Z)

1Department of Science, University of "Roma Tre", Rome, Italy.

Daniela Trisciuoglio (D)

3Institute of Molecular Biology and Pathology, National Research Council of Italy (CNR), c/o Sapienza University of Rome, Rome, Italy.
4Preclinical Models and New Therapeutic Agents Unit, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.

Roberto Antonioletti (R)

3Institute of Molecular Biology and Pathology, National Research Council of Italy (CNR), c/o Sapienza University of Rome, Rome, Italy.

Veronica Morea (V)

3Institute of Molecular Biology and Pathology, National Research Council of Italy (CNR), c/o Sapienza University of Rome, Rome, Italy.

Francesca Degrassi (F)

3Institute of Molecular Biology and Pathology, National Research Council of Italy (CNR), c/o Sapienza University of Rome, Rome, Italy.

Renata Cozzi (R)

1Department of Science, University of "Roma Tre", Rome, Italy.

Classifications MeSH